Director’s Major Stock Sale at Pacira Pharmaceuticals!

New insider activity at Pacira Pharmaceuticals ( (PCRX) ) has taken place on August 11, 2025.

Director Marcelo Bigal has recently sold 4,912 shares of Pacira Pharmaceuticals stock, amounting to a total transaction value of $116,267.

Recent Updates on PCRX stock

In the past 24 hours, Pacira Pharmaceuticals experienced a 4% increase in stock price to $24.71, following the announcement that Doma Perpetual Capital Management acquired a 5.7% stake in the company. Doma’s acquisition is intended to influence Pacira’s strategic direction without seeking full control. This development comes amid Pacira’s recent Q2 earnings call, which highlighted positive growth in EXPAREL, strategic partnerships, and improved financial metrics despite challenges in sales for certain products. The company reported a 6% year-over-year volume growth in EXPAREL, secured a new $300 million revolving credit facility, and announced a partnership with Johnson & Johnson MedTech to expand ZILRETTA’s market reach. Pacira also narrowed its full-year 2025 revenue guidance to $730 million-$750 million, reflecting confidence in its strategic initiatives and market position.

Spark’s Take on PCRX Stock

According to Spark, TipRanks’ AI Analyst, PCRX is a Neutral.

Pacira Pharmaceuticals’ overall stock score is primarily influenced by its strong earnings call performance, which highlights strategic partnerships and improved financial metrics. However, the company’s financial performance is hindered by high leverage and negative profitability, and the technical analysis suggests a lack of strong momentum. The valuation is also a concern due to the negative P/E ratio and absence of a dividend yield.

To see Spark’s full report on PCRX stock, click here.

More about Pacira Pharmaceuticals

YTD Price Performance: 37.37%

Average Trading Volume: 694,743

Technical Sentiment Signal: Sell

Current Market Cap: $1.13B